1-3 of 3
Merih Kizil, MD
Close
Sort by
Journal Articles

Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.

Meral Beksac, MD, Ender Soydan, MD, Vildan Ozkocaman, MD, Pervin Topcuoglu, MD, Berna Evranos, MD, Merih Kizil, MD, Aynur U. Bilgin, MD, Mutlu Arat, MD, Muhit Ozcan, MD, Onder Arslan, MD, Gunhan Gurman, MD, Osman Ilhan, MD
Journal: Blood
Blood (2007) 110 (11): 5096.
https://doi.org/10.1182/blood.V110.11.5096.5096
Published: 2007
Journal Articles

Marrow Plasma Cell Immunohistochemical Expression Profiles of Cyclins (A, D1, D2, D3), Cyclin Dependent Kinase Inhibitors (p16, p21) and Ki67: Predictors of Survival in Patients with Multiple Myeloma.

Meral Beksac, MD, Ender Soydan, MD, Selami Kocak Toprak, MD, Merih Kizil, MD, Gulsah Kaygusuz, MD, Isinsu Kuzu, MD
Journal: Blood
Blood (2005) 106 (11): 5117.
https://doi.org/10.1182/blood.V106.11.5117.5117
Published: 2005
Journal Articles

Interleukin-10(IL-10)1082-A and Tumor Necrosis Factor(TNF)-Alpha 238/308A Genotypes Are Associated with Earlier (Younger Than 55) Onset of Multiple Myeloma.

Meral Beksac, MD, Merih Kizil, MD, Ender A. Soydan, MD, Esin Serbest, Bcs, Klara Dalva, MD
Journal: Blood
Blood (2004) 104 (11): 4869.
https://doi.org/10.1182/blood.V104.11.4869.4869
Published: 2004